AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BerGenBio

Regulatory Filings Jan 8, 2019

3555_rns_2019-01-08_51ae3e64-d4b1-4e84-acbc-6d393cdc832f.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

BerGenBio to present company overview at Biotech Showcase 2019 during annual J.P. Morgan Conference in San Francisco

BerGenBio to present company overview at Biotech Showcase 2019 during annual J.P. Morgan Conference in San Francisco

Bergen, Norway, Jan 8th 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company focused on developing a pipeline of first-in-class AXL

kinase inhibitors to treat multiple cancer indications, announces that the

Company will be presenting a corporate overview at the Biotech Showcase 2019

in San Francisco today at 10:00 am PST.

The presentation will webcast live and the presentation is available for

download at the Company's website: www.bergenbio.com/investors/presentations/

Details for the presentation are as follows:

Biotech Showcase

Date: Tuesday, January 8, 2019

Time: 10:00 am PST

Room: Franciscan A (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street

-Ends-

Contacts

Richard Godfrey, CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

[email protected]

+47 917 86 513

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.